Stock Quote
Biomarin Pharmaceutical Inc. (BMRN.O) (Nasdaq)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View BMRN on other exchanges
$16.46
27 Nov 2009
-2.26%
$16.84
$16.50
373,181
$16.63
$16.17
$21.23
$9.93
1.40
927,334
BMRN.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Lapalme, Pierre | Chairman of the Board | -- |
| Bienaime, Jean-Jacques | Chief Executive Officer, Director | 3,676,570 |
| Cooper, Jeffrey | Chief Financial Officer, Senior Vice President | 891,671 |
Profile
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises three approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan... Full Description
Company Address
Biomarin Pharmaceutical Inc.
105 Digital Drive
Novato CA 94949
P: +1415.5066700
F: +1415.3827889
105 Digital Drive
Novato CA 94949
P: +1415.5066700
F: +1415.3827889
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Shire Plc. | £1,187.00 | +23.00 |
| Shire Plc. | -- | -- |
| The Medicines Company | $7.79 | -0.39 |
| BMRN.O | Industry | |
|---|---|---|
| P/E(TTM) | 121.83 | 3.66 |
| P/S(TTM) | 4.92 | 0.55 |
| ROI(TTM) | 2.50 | 1.88 |
| ROE(TTM) | 7.13 | 2.54 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.03 |
| EPS Est. (Current Year) | -0.05 |
| Total Revenue | $80.81M |
| Net Income | $6.64M |
| EPS | $0.06 |
